1,016 filings
Page 10 of 51
8-K
fi68wgnza
5 Nov 20
Cardiff Oncology Announces Third Quarter 2020 Results and Highlights
4:09pm
SC 13G
3tpfponiyl
4 Nov 20
Cardiff Oncology / Venrock Healthcare Capital Partners III ownership change
4:54pm
8-K
e8ocd58
20 Oct 20
Cardiff Oncology Presents Positive Efficacy and Biomarker Data from mCRPC Trial Demonstrating Ability of Onvansertib to Overcome Zytiga® Resistance
11:59am
SC 13G
xf5ehq
9 Oct 20
Cardiff Oncology / RA CAPITAL MANAGEMENT ownership change
4:29pm
3
xl7tye398uv0a53wwb8q
2 Oct 20
Cardiff Oncology / Rajeev M. Shah ownership change
4:30pm
8-K
ofdu8oi2dcigxj1 ff1
30 Sep 20
Cardiff Oncology Announces Proposed Public Offering
4:09pm
424B5
7fsyrv 83dd
30 Sep 20
Prospectus supplement for primary offering
4:00pm
424B5
927qmbw c4c1
29 Sep 20
Prospectus supplement for primary offering
4:00pm
8-K
j4cygrvkdmwkr2b
22 Sep 20
Regulation FD Disclosure
12:00am
8-K
a1psmu1 kr7zlfsg
17 Sep 20
Other Events
11:18am
4
f6fw 05r5xkn
17 Sep 20
Cardiff Oncology / GARY W PACE ownership change
9:42am
8-K
2v9t9 vqns2r1s8
15 Sep 20
Cardiff Oncology to Host Key Opinion Leader Call Discussing KRAS-Mutated Colorectal Cancer and Highlighting Data from Onvansertib Phase 1b/2 Trial
10:36am
8-K
bnld0f yieay4ppl
14 Sep 20
Cardiff Oncology to Present Data Further Demonstrating the Safety and Efficacy of Onvansertib in KRAS-Mutated Metastatic Colorectal Cancer Patients
11:55am
SC 13G
b9x0e 6stq2twg
28 Aug 20
Cardiff Oncology / Opaleye Management ownership change
5:15pm
8-K
nrantjf1xvhuj phwapx
11 Aug 20
Cardiff Oncology Announces Second Quarter 2020 Results and Highlights
4:04pm
8-K
ur5tdp k2l
4 Aug 20
Cardiff Oncology to Participate in Fireside Chat at the Virtual BTIG Biotechnology Conference
2:33pm
8-K
pd2ar9d9wm6 iqh
30 Jul 20
Cardiff Oncology to Participate in the William Blair Biotech Focus Conference
1:22pm
424B3
9mxrzjn 4dr5s6x3
13 Jul 20
Prospectus supplement
4:01pm